Compass Pathways leads race for first psychedelic drug approval, non-profit rivals

Compass Pathways is widely viewed as a leading candidate to bring the first psychedelic medicine to market. The company has advanced its therapy through clinical development and is positioned near the front of the approval pipeline.

A non-profit organization is also moving forward with its own psychedelic program, narrowing the gap between commercial and academic efforts. This parallel progress suggests the race for the first approved psychedelic could be closely contested.

The eventual approval will have significant implications for the emerging psychedelic sector, influencing investment, research focus, and potential treatment options for mental health conditions.